Lantheus Q2 revenue rises 2.7%, beats estimates

Lantheus Holdings

06/08/2026 12:15

Overview
Radiopharmaceutical company's Q2 revenue rose 2.7% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat consensus at $1.55
Company to be acquired by Curium in deal valued up to $8 bln

Outlook
Company is suspending previously issued full-year 2026 financial guidance due to pending merger

Result Drivers
PYLARIFY DECLINE - Sales of PYLARIFY fell 4.1% yr/yr in Q2
DEFINITY GROWTH - Sales of DEFINITY rose 5.2% yr/yr in Q2
SPECT REVENUE LOSS - SPECT revenue fell to zero from $31.9 mln a year ago

Company press release: ID:nGNX1z5081

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$388.20 mln
$362.42 mln (11 Analysts)
Q2 Adjusted EPS
Beat
$1.55
$1.30 (11 Analysts)
Q2 EPS
 
$1.11
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Lantheus Holdings, Inc. is $102.50, about 1% above its August 5 closing price of $101.50
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago

Reuters Recommended Reads
Aug 3 - Curium deepens radiopharma heft with up to $8 billion deal for Lantheus
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 5 - Caris Life Sciences Q2 revenue rises 45% on the back of molecular profiling services

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)